



MINDCURE

We believe it's possible

Corporate Presentation, April 2021

CSE:MCUR | OTC:MCURF | FRA:6MH

Disclaimer

This presentation (the “Presentation”) by MINDCURE Health Inc. (“MINDCURE”) is dated as of February, 2021. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor.

INDUSTRY INFORMATION

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities. This Presentation is not and under no circumstances is to be construed as prospectus, offering memorandum, advertisement or public offering of any securities referred to herein, nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of MINDCURE are referred to the entire body of publicly disclosed information regarding MINDCURE. The information is subject to material updating, revision and further amendment, and is qualified entirely by reference to MINDCURE’s publicly disclosed information.

This Presentation includes market and industry data and forecasts that have been obtained from third party sources, including industry publications. MINDCURE believes that the industry data and forecasts are generally reliable and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MINDCURE has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article.

No representation or warranty, express or implied, is made or given by or on behalf of MINDCURE or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. MINDCURE does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice.

Forward Looking Information

CAUTIONARY NOTE ON FORWARD LOOKING INFORMATION

This Presentation contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking information”) with respect to MINDCURE. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “will”, “projects”, or “believes” or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of products, or the efficacy thereof; the likelihood of success of any clinical trials; the likelihood of obtaining regulatory approval; the likelihood of obtaining patents or the efficacy of such patents once granted; the leadership team; the potential for the markets that MINDCURE is anticipating to access; and the factors described under the caption “Risk Factors” in MINDCURE’s final prospectus dated February 3, 2021 and documents incorporated by reference therein, which is available on MINDCURE’s profile at www.sedar.com. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made, including among other things assumptions about: MINDCURE’s ability to raise capital to complete its plans and fund its studies; the medical and commercial viability of the contemplated products being developed; the continued availability of key leadership personnel; and the ability of MINDCURE to raise additional capital as MINDCURE continues to develop its products. While MINDCURE considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. Many assumptions are based on factors and events that are not within the control of MINDCURE and there is no assurance they will prove to be correct.

Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended. To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MINDCURE’s financial condition and its operational history and experience in the industry. Readers are cautioned that this information may be not appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material.

No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them. There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All forward-looking information provided in this Presentation are qualified in their entirety by this cautionary statement, and MINDCURE disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. Accordingly, readers should not place undue reliance on forward-looking information.



MINDCURE

MINDCURE is transforming the world of pain. From despair and dependency to hope and healing, **we create Mental Wealth™**.

Our mission is to **innovate, identify, and commercialize** new methods, molecules, and products to address pain, neuroregeneration, and performance enhancement.

Psychedelics can heal a world in pain, and MINDCURE is leading the way.

How we are different: unlike many market participants we are using AI driven proprietary technology to drive near term revenue and optimize our clinical research paths.

THE PROBLEM: Pain is a global affliction leaving people dependent and in despair

THE PROMISE: Pain cures, neuroregeneration advancements and performance improvement will heal a world suffering

A Global Epidemic: Pain \$71 Billion - 2020

The **global pain market** wherein the **Neuropathic Pain** segment accounted for a **majority of the pain** management drugs market share and is expected to exhibit a prominent growth.¹

An Ill-Treated Epidemic \$85 Billion - 2027

As chronic disease cases escalate and populations surge, the **demand for pain management** drugs is anticipated to increase with over **90 million patients** struggling around the globe.³

An Under Researched Epidemic: Migraines \$3.51 Billion - 2026

Migraine cases have increased across the globe, and affect approximately **36 million Americans**, driving the global migraine drugs market from **\$1.29 Billion in 2018 to \$3.51 Billion by 2026.**⁴

A World Suffering needs a Cure.


1. <https://www.alliedmarketresearch.com/press-release/pain-management-therapeutics-market.html#:~:text=The%20global%20pain%20management%20drugs,3.8%25%20from%202020%20to%202027>
2. <https://www.bloomberg.com/news/articles/2020-01-07/psychedelic-mushroom-therapy-startup-edges-toward-fda-approval>
3. <https://www.globenewswire.com/news-release/2020/02/24/1989418/0/en/Migraine-Drugs-Market-To-Reach-USD-3-51-Billion-By-2026-Reports-And-Data.html>


MENTAL WEALTH MODEL

MINDCURE delivers innovation and commercialization of new methods, molecules, and products to address pain and performance across the spectrum of mental wellness.

From nootropics to psychedelics and digital therapeutics; we identify, research and develop products that treat the whole mind.

MINDCURE delivers short, near term and long term value creation with a business model strategically designed for growth and stability.






DIFFERENTIATED

Revenue: Horizons of revenue nearer term than many competitors

Research: While most psychedelics research programs are focussed on mood disorders, we focus on pain, neuroregeneration and performance.

Purpose Built: Our team and strategy are purpose built to exploit horizons of opportunity in the psychedelic revolution.

Diversified revenue streams and focused research originate from our **5 Spheres Strategy** of Product Discovery, Clinical Research, Formulation & Supply, Nootropic Formulations and Digital Therapeutics Technology



THE TECHNOLOGY

A Revolution in Managing Pain A Revenue Model that Gets Us There

DIGITAL HEALTH

\$312 Billion by 2025 as global demand for wellness on **demand rises** by near **18% a year**.¹

DIGITAL MEDICINE

DIGITAL THERAPEUTICS

\$13.8 Billion by 2027 as FDA begins to pre-certify digital health platforms with efficacy.¹

A renaissance in psychedelics means a revolution in treatments for psychological and physiological pain. **MINDCURE strikes where pain and mental health converge with innovations in research and digital therapeutics leading the revenue charge.**

1. <https://dtxalliance.org/2019/11/11/digital-health-digital-medicine-digital-therapeutics-dtx-whats-the-difference/>

RESEARCH BIOINFORMATICS PLATFORM


PsyCollage™

PsyCollage™ – Driving Research Discovery

MINDCURE's proprietary first-generation bioinformatics platform — **PsyCollage™**, accelerates MINDCURE's pre-clinical research by identifying and distilling data from documented research.

Using predictive correlative statistical analytics of existing data, **PsyCollage™** can mine and optimize the vast body of knowledge in psychedelic research.

Advancing MINDCURE's capabilities in identifying and determining priority research programs.



DIGITAL THERAPEUTICS TECHNOLOGY

iSTRYM™ Mental Health DTx

A.I. Driven Mental Health Patient Lifecycle Platform from Patient Assessment to Monitoring = Improving Outcomes.



CONCEPT ONLY

PRECISION MEDICINE & QUANTIFIED THERAPY



Research and Therapeutic Applications

Pre-Clinical, Clinical and Post Clinical Follow-up



Assessment Services

Screen, Assess, Collect Patient Data, Diagnoses



Support Suite

Aggregate Patient Data, Compounds, Protocols, Generate Patient Treatments Programs, Monitor



A.I. Driven Data Analysis

A.I. Analysis and Assessment of Patient Data, Generate New Insights



Ritual Suite


Set of prescribed post-treatment supplements, daily routines, and habits to reinforce positive patient outcomes

TECHNOLOGY PATH TO REVENUE

iSTRYM™

MINDCURE will be the leader in the B2B development of iSTRYM™ as it has a SaaS strategy with plans to submit for pre-certification on the SaMD program with the FDA.

SaMD allows for insurance coverage for the technology as a service.





ORGANIZATIONAL CATALYSTS & MILESTONES

Strong News Flow Predicted

Q1 2021

- ✓ bring forward pre/post psychedelic nootropic supplement
- ✓ run beta of the Psycollage component of iSTRYM™ driving decision making for drug lead optimization
- ✓ confirm the beta deployment partnership with ATMA for psychedelic therapy patient data collection
- ✓ initiate partnership with unstructured data AI engine to integrate into iSTRYM™
- ✓ primary investigator secured for our first psychedelic research program

Q2 2021

- ✓ patent filing on proprietary digital therapeutics platform
- ✓ PsyCollage™ bioinformatics platform undergoes beta testing
- new molecular entity > medchem being done at University of the Sciences
- research relationship secured for our second psychedelic program
- with iSTRYM™ — securing biometric partner and AI partnership to drive integration protocol optimization

Q3 2021

- initiate major research partnership
- patent filing on proprietary formulation
- update on psychedelic research clinic partnerships with iSTRYM™


Q4 2021

- iSTRYM™ fully functional beta deployment into multiple psychedelic treatment facilities.
- cGMP scale up on the iboga molecule


✓ Accomplished per plan

THE RESEARCH FOCUS BY COMPOUND


Investigating Classic Psychedelics in the Discovery of New Classes of Medicines for Pain and Trauma.



IBOGAINE,
Novel synthetics of natural IBOGA-derived compounds and precursors



KETAMINE, KETAMINE-ANALOGUES,
targeting well established receptors and receptor motifs



PSILOCYBIN, PSILOCIN, BAEOCYSTIN
and NME analogues

Priority Areas of Drug Discovery and Lead Optimization of proprietary NME's:

PRIMARY INDICATIONS

Head Trauma
Spinal Cord Injury
Neuroregeneration (*remediation*)
Idiopathic pain

SECONDARY INDICATIONS

Depression
AD(H)D
Addiction

Priority Clinical Indications (combos of classic psychedelics):

Traumatic Brain Injuries (*rehabilitation & recovery*)
Migraines
Cluster Headaches
Neuropathic Pain
Treatment Resistant Mood Disorders

*REGULATORY PATH: IREB approvals, IND, orphan and breakthrough status filings.

NOOTROPICS & ADAPTOGENS

A Moment of Opportunity: The Functional Market

\$5.32 Billion nootropics market by 2026⁶

Surging Demand

The **demand for functional mushroom products has rapidly increased** over the past 24 months and is projected to continue strong growth through 2026.¹

Consumer Trends

Individual eating habits are shifting towards consuming more natural, healthy food products and dietary supplements rather than less healthy alternatives.¹

Cognitive Benefits

Functional mushrooms are a rich source of antioxidants² and may **offer cognitive³, digestive,⁴ and immunity benefits⁵ as well as aid in boosting energy levels.³**

R&D Investment

Food and supplement companies are **increasing their R&D spending on functional mushroom products** to develop new formulations and better understand the benefits.¹

FORMULATION

- Expert Formulators
- Patentable pre & post psychedelic formulations

GENUINE  HEALTH

greens+

vega

REGULATION

- Natural Product Numbers
- US proposition 65 compliance

DISTRIBUTION

- Business to Consumer
- iSTRY™ integration & reordering 2022

1. <https://www.mordorintelligence.com/industry-reports/functional-mushroom-market> • 2. <https://pubmed.ncbi.nlm.nih.gov/14630595/> • 3. <https://pubmed.ncbi.nlm.nih.gov/15857210/> • 4. <https://pubmed.ncbi.nlm.nih.gov/25006989/> • 5. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774877/> - The references above are not meant to imply that any of our products treat, cure, or diagnose any disease or human condition. References to clinical studies and pre-clinical studies may use varying dosages and may not represent the dosages or subsequent results of products we sell; however, the references provided are pertinent to the subject supplement itself. References provided are intended for research and informational purposes only and do not represent the entire body of knowledge available on the subject(s) referenced; nor do they represent all possible outcomes associated with the subject(s) referenced including, but not limited to, adverse effects, precautions, or chemical interactions within the human body. • 6. <https://www.globenewswire.com/news-release/2020/02/19/1987135/0/en/Nootropics-Market-To-Reach-USD-5-32-Billion-By-2026-Reports-And-Data.html>

NOOTROPIC FORMULATIONS

Focus, Energy, Immunity, Teen Restlessness, Pre-Psychedelic Preparation, Post-Psychedelic Integration



Functional Mushrooms are a rich source of antioxidants² and may offer cognitive³, digestive⁴ and immunity benefits⁵ as well as aid in boosting energy levels³

“Mushrooms have many helpful nutrients, including beta glucans for immune enhancement, ergothioneines for antioxidative potentiation, nerve growth stimulators for helping brain function, and antimicrobial compounds for limiting viruses.”⁶

—Paul Stamets

¹<https://www.mordorintelligence.com/industry-reports/functional-mushroom-market> • ²<https://pubmed.ncbi.nlm.nih.gov/14630595/> • ³<https://pubmed.ncbi.nlm.nih.gov/15857210/> • ⁴<https://pubmed.ncbi.nlm.nih.gov/25006989/> • ⁵<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774877/> • ⁶<https://fungi.com/blogs/articles/place-mushrooms-in-sunlight-to-get-your-vitamin>
The references above are not meant to imply that any of our products treat, cure, or diagnose any disease or human condition. References to clinical studies and pre-clinical studies may use varying dosages and may not represent the dosages or subsequent results of products we sell; however, the references provided are pertinent to the subject supplement itself. References provided are intended for research and informational purposes only and do not represent the entire body of knowledge available on the subject(s) referenced, nor do they represent all possible outcomes associated with the subject(s) referenced including, but not limited to, adverse effects, precautions, or chemical interactions within the human body.

PURPOSE BUILT LEADERSHIP

We Believe in Focus, Drive and Innovation



Kelsey Ramsden *CEO and President*

An accomplished keynote speaker and published author, Kelsey possesses over 15 years of experience founding, scaling and operating innovative companies across Canada and the Caribbean. She has built multiple 8-figure businesses from the ground up and has twice been named Canada's Top Female Entrepreneur. Kelsey also serves on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member teaching Design Thinking. Kelsey holds an MBA from the Richard Ivey School of Business at the University of Western Ontario.



Geoff Belair *CTO*

With over 30 years of experience in the fintech industry, Mr. Belair has built innovative and industry-leading technology solutions to drive operations forward. He possesses a unique combination of software architecture and design experience with a deep understanding of technology adoption and change management. Geoff has led multidisciplinary teams throughout his career, and delivered ground-breaking and innovative solutions throughout the fintech industry. As a senior architect and creator of the Integration Services Team with Fincentric Corporation, a banking solutions company, he led successful implementations at Stanford University's Bank in Palo Alto California and American Express Bank in Singapore. Most recently, he served as Vice President of Information Technology at Westland Insurance.olds a faculty position at UBC and continues to lecture for the UBC Department of Surgery.



Dr. Ryan Hartwell, Ph.D. *Chief Scientific Officer*

Dr. Hartwell, an entrepreneur with a strong record of successful Biotech startups, having co-founded ATS Biotech Inc., an advanced, biomedical wound care (medical device) company and Birch BioMed (BBM), where he is also co-inventor of BBM's FS2 and AI-001 cell therapy. As a university and workshop lecturer with first-hand experience in FDA, EU, HC, CFDA. Dr. Hartwell brings a wealth of experience to Mind Cure's regulatory affairs and product research. Dr. Hartwell received his Ph.D. in Experimental Medicine at UBC, receiving the Vancouver Coastal Health Research Institute Award for Top Graduating Doctoral Student. Dr. Hartwell holds a faculty position at UBC and continues to lecture for the UBC Department of Surgery.



Michael Wolfe *CFO*

Mr. Wolfe has over 30 years' experience in finance, accounting, private equity, and business valuation. He was most recently the CFO of Baylin Technologies Inc., a TSX listed company in the wireless communications industry. Prior to joining Baylin, Michael was the CFO of several mid-market Canadian companies, including Masstech Group Inc., a software company in the broadcast industry. As a General Partner at VenGrowth Capital Partners Inc., Michael had a successful track record in acquisitions, management buyouts, growth financings, and recapitalizations in diverse industries such as cable, broadcast, manufacturing, insurance, oil field services, and global logistics. Mr. Wolfe has also served as a director for several private and public companies, including as a member of audit and other independent committees. He earned a CPA, CA designation, a Chartered Business Valuator designation, an MBA from McMaster University, and a BA (Business and Economics) from the University of Western Ontario.

PURPOSE BUILT LEADERSHIP

We Believe in Discipline and Trust



Dr. Dan Engle, M.D. Psychiatry *Principal Investigation*

Dr. Engle is world-renowned for his specializations in psychiatry and neurology. With a background in integrative psychiatry, neurocognitive restoration, peak performance medicine and psychedelic research, Dr. Dan Engle helps individuals shift from illness and trauma to health and happiness. His trans-disciplinary approach focuses on healing the body and brain, the heart and mind and, finally, integrates the spirit to help individuals optimize all aspects of health for sustained fulfillment. He received his medical degree from the University of Texas in San Antonio, his psychiatry residency degree from the University of Colorado in Denver and his Child and Adolescent Psychiatry Fellowship degree from Oregon Health and Sciences University.



Dr. Wolfram Tetzlaff *Scientific Advisor*

Dr. Wolfram Tetzlaff is the Director of ICORD and a Professor in the Departments of Zoology and Surgery at the University of British Columbia. He also holds the John and Penny Ryan British Columbia Leadership Chair in Spinal Cord Research. He obtained his M.D. at the University of Essen, completed his Dr. Med. at Ruhr-University Bochum and his Ph.D. at the University of Calgary. Research in Dr. Tetzlaff's laboratory is focused on neural protection and neural repair, working on strategies to protect the spinal cord and brain in the early phases after injury, including with nutrition, and to promote recovery after spinal cord/brain injury by stimulating endogenous stem cells.



Hamilton Morris *Scientific Advisor*

Hamilton Morris is a chemist, filmmaker, and science journalist. He is the director of the award winning documentary series Hamilton's Pharmacopeia in which he explores the chemistry and traditions surrounding psychoactive drugs. His research has allowed him to study psychoactive plants, fungi, and chemicals as well as the culture that surrounds them in more than thirty countries using an interdisciplinary approach that combines anthropology and chemistry. Hamilton attended the University of Chicago and The New School in New York City, where he studied anthropology and science. He frequently consults with media on the subject of psychoactive drugs and conducts pharmacological research at the University of the Sciences in Philadelphia.



Jason Wallach, Ph.D. *Scientific Advisor*

Dr. Jason Wallach is an instructor in the Department of Pharmaceutical Sciences as well as the Substance Use Disorders Institute at the University of the Sciences (Philadelphia, PA). He also holds an adjunct appointment at Cooper Medical School of Rowan University (Camden, NJ) and is an author on over 20 publications in peer-reviewed journal articles as well as numerous book chapters and popular press articles. Dr. Wallach and his team spend time in the lab researching how existing drugs, including psychoactive and dissociative drugs, and new formulations can best help patients. Dr. Wallach has a Ph.D. in Pharmacology and Toxicology from University of the Sciences and a BS in Cell and Molecular Biology from Indiana University of Pennsylvania.

Capitalization Summary *(Feb 25, 2021)*


CAP TABLE

Shares outstanding	92.6M
Options Outstanding	8.7M
Warrants outstanding	29.9M
Fully Diluted	131.2M


KEY STATISTICS


Price (02-25-2021)	C\$0.56
Market Cap	\$51.9M
52 week high/low	\$0.90 / \$0.53
Avg Daily Volume 3M	860,000

MINDCURE HEALTH INC. (CNSX:MCURE) SHARE PRICE



OWNERSHIP BREAKDOWN





WHY INVEST NOW

**Clear path
to near-term
revenue**

**Purpose built
scientific
discovery team**

**Proprietary
digital therapeutics
platform**



MINDCURE

We believe it's possible

CONTACT

investors@mindcure.com

1-888-593-8995

CSE:MCUR | OTC:MCURF | FRA:6MH

APPENDIX 1: RESEARCH PATHWAY

Priority Indications

PRIORITY REVENUE	DISCOVERY	LEAD OPTIMIZATION	PHASE 1 AND PHASE 2 OR PHASE 1/2A
Migraine	 		
Cluster Headache	 		
Traumatic Brain Injuries (TBI)	 		
Neuropathic Pain	 		
Treatment Resistant Mood Disorders (TRMD)	 		

-  Combination therapies of classic psychedelic compounds (psilocybin, ketamine, ibogaine)
-  All proprietary NME's from Mind Cure's R&D or in-licensed